Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient

Int Clin Psychopharmacol. 2006 May;21(3):181-4. doi: 10.1097/01.yic.0000182119.51672.f0.


The introduction of atypical antipsychotics into clinical practice has lead to an increase of adverse metabolic effects in psychotic patients. Amisulpride is a substituted benzamide derivative, and its use is associated with a lower risk of weight gain compared to other atypical antipsychotics. The case of an acute and excessive weight increase in a female first-episode schizophrenic patient who was treated with amisulpride monotherapy is reported. The improvement in psychopathology was remarkable. However, the patient gained 12.9 kg of body weight in the first 2 months of amisulpride administration and a total of 17.3 kg, 6 months after initiation of the treatment. Glucose and insulin levels, as well as a glucose tolerance test, remained normal throughout the observation period.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Amisulpride
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use
  • Female
  • Humans
  • Schizophrenia / drug therapy*
  • Schizophrenia / physiopathology
  • Sulpiride / adverse effects
  • Sulpiride / analogs & derivatives*
  • Sulpiride / therapeutic use
  • Time Factors
  • Weight Gain / drug effects*


  • Antipsychotic Agents
  • Sulpiride
  • Amisulpride